Annals of Surgical Oncology

, Volume 22, Issue 7, pp 2365–2371 | Cite as

Clinical Significance of Extracapsular Invasion at Sentinel Lymph Nodes in Breast Cancer Patients with Sentinel Lymph Node Involvement

  • Hideo Shigematsu
  • Kenichi Taguchi
  • Hiroko Koui
  • Shinji Ohno
Breast Oncology

Abstract

Background

A certain number of patients have extracapsular invasion (ECI) at the sentinel lymph node (SLN), but only a few reports describe its clinical significance. This study aimed to determine the clinical significance of ECI at SLN in breast cancer patients with involved SLN.

Methods

This study evaluated ECI at SLN in 131 consecutive SLN-positive patients who underwent axillary lymph node dissection between 2003 and 2008 at the National Kyushu Cancer Center with regard to their long-term prognosis and non-SLN metastasis.

Results

Of the 131 patients, 46 (35 %) tested positive for ECI at SLN. Of these 46 patients, 61 % (28/46) had non-SLN metastasis compared with 28 % (24/85) in ECI-negative group (χ 2 test; P < 0.001). Multivariate analysis showed that ECI at SLN is significantly predictive for non-SLN metastasis [hazard ratio (HR) 3.2; 95 % confidence interval (CI) 1.4–7.1; P = 0.005]. The 5-year recurrence-free survival (RFS) rates were 71.3 % in the ECI-positive group and 89.9 %in the ECI-negative group (P = 0.001, log-rank test). Cox-regression analysis showed that ECI at SLN independently predicts lower RFS (HR 4.5; 95 % CI 1.8–11.7; P = 0.002).

Conclusions

The findings show that ECI at SLN is an independent predictor of both non-SLN metastasis and poor prognosis for breast cancer patients with involved SLN. The clinical significance of ECI at SLN in operable-stage breast cancer warrants further study.

Keywords

Sentinel Lymph Node Sentinel Lymph Node Biopsy Axillary Lymph Node Dissection Operable Breast Cancer Sentinel Lymph Node Metastasis 

Notes

Disclosure

The authors declare that they have no competing interests.

References

  1. 1.
    Fisher B, Redmond C, Fisher ER, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med. 1985;312:674–81.PubMedCrossRefGoogle Scholar
  2. 2.
    Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347:567–75.PubMedCrossRefGoogle Scholar
  3. 3.
    Sanghani M, Balk EM, Cady B. Impact of axillary lymph node dissection on breast cancer outcome in clinically node negative patients: a systematic review and meta-analysis. Cancer. 2009;115:1613–20.PubMedCrossRefGoogle Scholar
  4. 4.
    Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002;20:3628–36.PubMedCrossRefGoogle Scholar
  5. 5.
    Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007;25:3657–63.PubMedCrossRefGoogle Scholar
  6. 6.
    Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927–33.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Kapoor NS, Sim MS, Lin J, Giuliano AE. Long-term outcome of patients managed with sentinel lymph node biopsy alone for node-negative invasive breast cancer. Arch Surg. 2012;147:1047–52.PubMedCrossRefGoogle Scholar
  8. 8.
    Werkoff G, Lambaudie E, Fondrinier E, et al. Prospective multicenter comparison of models to predict four or more involved axillary lymph nodes in patients with breast cancer with one to three metastatic sentinel lymph nodes. J Clin Oncol. 2009;27:5707–12.PubMedCrossRefGoogle Scholar
  9. 9.
    Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569–75.PubMedCrossRefGoogle Scholar
  10. 10.
    Lyman GH, Temin S, Edge SB, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2014;32:1365–83.PubMedCrossRefGoogle Scholar
  11. 11.
    Chen AY, Halpern MT, Schrag NM, Stewart A, Leitch M, Ward E. Disparities and trends in sentinel lymph node biopsy among early-stage breast cancer patients (19982005). J Natl Cancer Inst. 2008;100:462–74.PubMedCrossRefGoogle Scholar
  12. 12.
    Heneghan HM, Prichard RS, Devaney A, et al. Evolution of breast cancer management in Ireland: a decade of change. BMC Surg. 2009;9:15.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Weaver DL, Ashikaga T, Krag DN, et al. Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med. 2011;364:412–21.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Fujii T, Yanagita Y, Fujisawa T, Hirakata T, Iijima M, Kuwano H. Implication of extracapsular invasion of sentinel lymph nodes in breast cancer: prediction of nonsentinel lymph node metastasis. World J Surg. 2010;34:544–8.PubMedCrossRefGoogle Scholar
  15. 15.
    van la Parra RF, Peer PG, de Roos WK, Ernst MF, de Wilt JH, Bosscha K. A simple risk score to predict the presence of non-sentinel lymph node metastases in breast cancer patients with a positive sentinel node. World J Surg. 2014;38:1070–6.CrossRefGoogle Scholar
  16. 16.
    Gooch J, King TA, Eaton A, et al. The extent of extracapsular extension may influence the need for axillary lymph node dissection in patients with t1-t2 breast cancer. Ann Surg Oncol. 2014;21:2897–903.PubMedCrossRefGoogle Scholar
  17. 17.
    Yajima R, Fujii T, Yanagita Y, et al. Prognostic value of extracapsular invasion of axillary lymph nodes combined with peritumoral vascular invasion in patients with breast cancer. Ann Surg Oncol. 2014.Google Scholar
  18. 18.
    Hetelekidis S, Schnitt SJ, Silver B, et al. The significance of extracapsular extension of axillary lymph node metastases in early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2000;46:31–4.PubMedCrossRefGoogle Scholar
  19. 19.
    Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287–312.PubMedCrossRefGoogle Scholar
  20. 20.
    Colzani E, Liljegren A, Johansson AL, et al. Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis, age, and tumor characteristics. J Clin Oncol. 2011;29:4014–21.PubMedCrossRefGoogle Scholar
  21. 21.
    Luporsi E, Andre F, Spyratos F, et al. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat. 2012;132:895–915.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999–2009.PubMedCrossRefGoogle Scholar
  23. 23.
    Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–26.PubMedCrossRefGoogle Scholar
  24. 24.
    Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27:1160–7.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Kadoya T, Aogi K, Kiyoto S, Masumoto N, Sugawara Y, Okada M. Role of maximum standardized uptake value in fluorodeoxyglucose positron emission tomography/computed tomography predicts malignancy grade and prognosis of operable breast cancer: a multi-institute study. Breast Cancer Res Treat. 2013;141:269–75.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Ohara M, Shigematsu H, Tsutani Y, et al. Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer: usefulness for malignant grade of triple-negative breast cancer. Breast. 2013;22:958–63.PubMedCrossRefGoogle Scholar
  27. 27.
    Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol. 2005;23:2020–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009;101:1446–52.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Donegan WL, Stine SB, Samter TG. Implications of extracapsular nodal metastases for treatment and prognosis of breast cancer. Cancer. 1993;72:778–82.PubMedCrossRefGoogle Scholar
  30. 30.
    Ilknur GB, Hilmi A, Tulay C, et al. The importance of extracapsular extension of axillary lymph node metastases in breast cancer. Tumori. 2004;90:107–11.PubMedGoogle Scholar
  31. 31.
    Stitzenberg KB, Meyer AA, Stern SL, et al. Extracapsular extension of the sentinel lymph node metastasis: a predictor of nonsentinel node tumor burden. Ann Surg. 2003;237:607–12; discussion 612–603.PubMedCentralPubMedGoogle Scholar
  32. 32.
    Degnim AC, Reynolds C, Pantvaidya G, et al. Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram. Am J Surg. 2005;190:543–50.PubMedCrossRefGoogle Scholar
  33. 33.
    Mittendorf EA, Hunt KK, Boughey JC, et al. Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. Ann Surg. 2012;255:109–15.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2014

Authors and Affiliations

  • Hideo Shigematsu
    • 1
  • Kenichi Taguchi
    • 2
  • Hiroko Koui
    • 3
  • Shinji Ohno
    • 3
  1. 1.Department of Surgical Oncology, Research Institute for Radiation Biology and MedicineHiroshima UniversityHiroshimaJapan
  2. 2.Department of PathologyNational Kyushu Cancer CenterFukuokaJapan
  3. 3.Department of Breast OncologyNational Kyushu Cancer CenterFukuokaJapan

Personalised recommendations